Business
Krystal Biotech Reports First Quarter 2020 Financial Results and Provides Update on Operational Progress
KB105 interim Phase 1/2 clinical data for treatment of autosomal recessive congenital ichthyosis (ARCI) to be announced at the Society for Investigative
About this update from Krystal Biotech, Inc.
[{"type":"text","content":"KB105 interim Phase 1/2 clinical data for treatment of autosomal recessive congenital ichthyosis (ARCI) to be announced at the Society for Investigative Dermatology (SID) Annual Meeting in May 2020\n B-VEC Phase 3 pivotal study anticipated to start in 1H 2020 B-VEC Phase 1/2 clinical data and statistical analysis to be presented at the Society for Investigative Dermatology (SID) Annual Meeting in May 2020 KB407 in vitro pharmacology data to treat cystic fibrosis to be announced at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in May 2020 Ended the quarter with cash, cash equivalents and short-term investments of $186.7 million PITTSBURGH, May 04, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing a new class of transformative medicines to treat diseases caused by gene or protein dysfunction, reported financial results and key operational progress updates for the first quarter ending March 31, 2020. “In 2020, we anticipate treating patients across three different clinical trials for skin diseases and conditions and remain committed to developing our pipeline to ensure that that we can translate its potential into treatments for patients affected by severe diseases,” said Krish S. Krishnan, chairman and chief executive officer. “We are pleased to report that our manufacturing batch has been cleared for the upcoming B-VEC Phase 3 pivotal study. We are presently on track to start the pivotal study in the first half of 2020, barring any COVID-19 delays. We are also encouraged by the pre-clinical data to date on KB407, with potential to treat cystic fibrosis, that demonstrates the breadth of our STAR-D platform and are excited that we have an opportunity to share this at ASGCT.” Upcoming events: Presentation of “First-in-Human use of a Novel In Vivo Gene Therapy for the Treatment of Autosomal Recessive Congenital Ichthyosis: Results of Phase 1/2 placebo controlled trial,” by Dr. Amy S. Paller, M.D. (Chair, Department of Dermatology, Northwestern University), at the Society for Investigative Dermatology (SID) annual meeting, May 13-16 2020.Presentation of “In vivo correction of dystrophic epidermolysis bullosa by direct cutaneous COL7A1 gene replacement: results of Phase 1/2 trial,” by Dr. Peter Marinkovich, M.D. (Associate Professor of Dermatology, Stanford...